Future studies may target ADD3 depleted tumors as a novel therapeutic approach utilizing synthetic lethality, which can be developed to target gene defects in tumors with ADD3 deletion, similar to the concept of using PARP inhibitors exclusively for BRCA-mutated breast tumors. This evidence concerns the gene ADD3 and breast neoplasm.